Order final: Divestiture on the clock

Hikma Pharmaceuticals may acquire Baxter Healthcare Corporation’s generic injectables business, a $112 million proposed deal that the FTC approved on June 7.

Within 10 days of the deal closing, Hikma must...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

Try FTCWatch FREE for 30 days

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch

Current Issue: 1027
Next Issue: Jun 7, 2022

Browse Archives

In this Issue:

Advocacy group seeks information on Kanter’s ethical obligations
Calendar
Political gridlock could prevent FTC from getting disgorgement powers
Khan disputes Republican narrative about merger enforcement efficiency
On the Shelf: No major fix for lax data security
Frontier to pay $8.5 million for deceiving customers about Internet speeds
Cross-border fraud reports doubled last year
The road to FTC rulemaking looks far from smooth
Senators demand investigation into gun marketing to kids
The Credit Game forced to shut down credit repair scheme
Privacy Corner: Meet Sara Collins of Public Knowledge
People
FTC advisers herald slamming brakes on remedies
Biden tells FTC to address price gouging of baby formula
Neil Averitt commentary: Protecting businesses from telemarketing scams
People
Bolster children’s online privacy rights, London group urges FTC
Calendar
HSR filings in US drop in February, March, reflecting global uncertainties
Hatch had large influence on antitrust during Senate career

RSS Feed